ResMed set to awaken

This manufacturer of treatments for sleep apnea has faced a number of problems over the past year, but its future looks brighter.

The sharemarket has been a bit hairy over the past few weeks, which is just how we like it – throwing up plenty of opportunities. In these circumstances, therefore, it might seem a little perverse that our Buy recommendation for October has actually risen 10% over the past six months and 5% over the past three. As we shall see, though, there are good reasons for renewed confidence, and the market’s current funk may in fact be helping to keep a lid on the share price.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles